Biovie Inc.
BIVIW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001580149
In the last 90 days, Biovie Inc. insiders filed 4 open-market purchases and 0 sales; 8 institutions reported holding it in 13F filings for Q2 2026, worth $1.07M in total; no superinvestor holds it.
Other share classesBIVI
Key figures
- Insider buysLast 90 days, $49.1K in total
- 4
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 8
- 13F valueReported value at the end of Q2 2026
- $1.07M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding BIVIW, Q2 2026
No superinvestor reported holding BIVIW at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Biovie Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 28, 2026 (view filing)9:01 PM ET | Aug 28 | Same day | Palumbo Joseph MChief Medical Officer | PPurchase | +4.84K | $2.16 | +$10.5K | +406.0%6.04K after | |
| Aug 28, 2026 (view filing)9:01 PM ET | Aug 28 | Same day | Chappell Amy SuzonDirector | PPurchase | +727 | $2.16 | +$1.57K | New position727 after | |
| Aug 28, 2026 (view filing)8:58 PM ET | Aug 28 | Same day | Kim Joanne WendyChief Financial Officer | PPurchase | +2.50K | $2.18 | +$5.45K | +265.7%3.44K after | |
| Aug 28, 2026 (view filing)8:57 PM ET | Aug 27 | 1 day | Do Cuong VPresident & CEO | PPurchase | +15.2K | $2.08 | +$31.6K | +1,677.0%16.1K after | |
| Aug 13, 2025 (view filing) | Aug 7 | 6 daysLate | Do Cuong VPresident & CEO | PPurchase | +5.00K | – | – | +100.2%9.99K after | |
| Aug 13, 2025 (view filing) | Aug 7 | 6 daysLate | Do Cuong VPresident & CEO | PPurchase | +5.00K | – | – | –5.05K after | Derivative |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Do Cuong VPresident & CEO | PPurchase | +10.0K | – | – | +2.3%435.9K after | |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Do Cuong VPresident & CEO | PPurchase | +5.00K | – | – | –5.00K after | Derivative |
| Dec 6, 2023 (view filing) | Dec 1 | 5 daysLate | Gorlin SteveDirector | SSale | −75.7K | $1.69 | −$127.9K | −62.0%46.4K after | |
| Dec 1, 2023 (view filing) | Nov 30 | 1 day | Do Cuong VPresident & CEO | PPurchase | +10.0K | $1.78 | +$17.8K | +17.0%68.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Biovie Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Diametric Capital, LP | 750,000 | $337.5K | 0.04% | 00.0% | Unchanged |
| Warberg Asset Management LLC | 613,426 | $276.0K | 0.08% | +156,797+34.3% | Added |
| Armistice Capital, LLC | 500,000 | $225.0K | 0.01% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 186,621 | $84.0K | 0.01% | 00.0% | Unchanged |
| MYDA Advisors LLC | 159,800 | $71.9K | 0.02% | −9,113−5.4% | Reduced |
| Heights Capital Management, Inc | 90,000 | $40.5K | 0.01% | 00.0% | Unchanged |
| Armstrong Advisory Group, Inc | 65,900 | $29.7K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 13,884 | $6.25K | 0.00% | +2,750+24.7% | Added |